Provention Bio has selected Netherlands-based Intravacc to lead product development and manufacturing of clinical trial material for Provention’s coxsackievirus B (CVB) vaccine (PRV-101). France-based L2D Services SARL/Leads-To-Development (L2D) is providing development, regulatory and project management support to ensure rapid progress of PRV-101 into clinical development. CVB, an enterovirus, has been identified as a possible common trigger for type 1 diabetes (T1D) onset. Vaccination...